FFB and Sanofi Sign a Collaboration Agreement to Boost Therapy Development

May 22, 2014

To advance the research and development of inherited retinal-disease therapies, the Foundation Fighting Blindness Clinical Research Institute (FFB CRI) and Sanofi, a global pharmaceutical company headquartered in France, have entered into a two-year agreement to regularly exchange scientific information.

“We are very pleased with Sanofi’s interest in leveraging our expertise in the inherited retinal-disease sector,” says Patricia Zilliox, Ph.D., chief drug development officer at FFB CRI. “Ultimately, we believe this relationship can translate to more therapies for more people.”

Recognizing FFB CRI’s extensive knowledge of the inherited retinal-disease research landscape, Sanofi will use the information sharing to identify potential therapies, advance clinical development of emerging treatments and expand its presence in the orphan ophthalmic-disease marketplace. Likewise, Sanofi can provide vast drug development expertise and resources for advancing promising therapeutic candidates that could come out of FFB CRI’s research program.

“We are delighted to be partnering with Sanofi to share scientific and therapeutic knowledge,” says William T. Schmidt, chief executive officer at FFB. “It affirms our leadership role in driving cutting-edge, retinal-disease research, and most important, it gives our sight-saving work a strong presence in the international pharmaceutical community.”